ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check

Core Viewpoint - ImmunityBio Inc. has seen a significant stock increase of over 300% year-to-date, despite a recent decline in premarket trading. The company announced that its pivotal trial for Anktiva has been confirmed as adequately powered by the Independent Data Monitoring Committee (IDMC) [1][2]. Group 1: Trial and Results - The IDMC confirmed that the current enrollment of 366 participants is sufficient to detect a clinically meaningful difference in complete response (CR) rates for the QUILT-2.005 trial, which evaluates Anktiva in combination with Bacillus Calmette-Guérin (BCG) for non-muscle invasive bladder cancer [2]. - An interim analysis was conducted upon reaching a pre-specified 50% evaluable threshold, verifying that the enrolled patients provide adequate statistical power to detect the expected difference in CR rates [3]. - ImmunityBio has reported promising results from earlier trial phases, indicating a prolonged duration of complete remission in patients [3]. Group 2: Regulatory and Pipeline Developments - The company plans to submit a supplemental Biologics License Application based on final data analysis in 2026 and is advancing its phase 1 trial (QUILT-3.076), which combines M-ceNK cells with Anktiva [4]. - The FDA has determined that a direct-to-consumer advertisement for Anktiva was misleading, making unsupported claims about the drug's effectiveness [5]. Group 3: Market and Analyst Insights - The National Comprehensive Cancer Network has updated its guidelines to include Anktiva plus BCG for BCG-unresponsive NMIBC with papillary-only disease [6]. - Analyst consensus rates the stock as a Buy, with an average price target of $12.57, and recent analyst actions include maintaining a Buy rating with targets of $23.00 and $13.00 from different firms [6][7].